Skip to main content
. 2013 Mar 7;8(3):e56044. doi: 10.1371/journal.pone.0056044

Table 1. Summary of Key Epidemiologic Inputs of Effectiveness.

Author,Year InitialPrevalenceof LTBI AnnualReactivation rate TSTSensitivity TST Specificity- NO BCG TST Specificity-BCG IGRASensitivity IGRASpecificity LTBI Completionrate Efficacy of Full LTBI regimen Probability of adverse event
Burgos, 2009 58% 1.10% NA NA NA 95% 98% 80% 69% 18%
de Perio, 2009 5% 0.02% 67% 98% 70% 76% 96% 31% 90% 0.60%
Deuffic-Burban, 2010 41% 0.24% 73% NA 60% 76% 96% 57% 69% 0.001%
Diel, 2007 11% 0.30% 90% NA 61% 90% 100% 100% 80% 0%
Diel, 2007 28% 0.30% 93% NA 25% 95% 100% 100% 80% 0%
Kowada, 2010 5% 0.28% 80% 97% 59% 84% 99% 80% 70% 0.30%
Kowada, 2010 36% 0.15% NA NA NA 81% 99% 80% 70% 0.30%
Kowada, 2008 20% 0.28% 71% 98% 15% 76% 96% 90% 70% 1.30%
Linas, 2011 (adult close contacts) 43.7% 1.02% 89% 98% NA 83% 99% 48% 90% 1%
Linas, 2011(recent adult immigrants to US) 41.4% 0.08% 89% NA 92% 83% 99% 51% 90% 1%
Marra, 2008 21% 0.41% 99% 95% 36% 99% 96% 28% 90% 0.30%
Oxlade, 2007 35% 0.10% 95% 98% 60% 95% 98% 21% 80% 1%
Pareek, 2011 23% 0.25% NA NA NA 84% 99% 81% 65% 0.20%
Pooran, 2010 30% 1.25% 85 80%* NA 95%/89%** 100%/95%** 72% 65% 0.3%

More detail provided in Table S1.

*

BCG status of population not specified.

**

T Spot/IGRA.